Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
CORE PRINCIPLE / WORLD VISION
CORE PRINCIPLE / WORLD VISION
VALUES
VALUES
History
History of Santen
Corporate Executives
Top Management
Corporate Executive
Corporate Governance
Corporate Governance
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
Santen 2030
Santen 2030
Medium-term Management Plan
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Product Process: R&D
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Quality Compliance
The Ophthalmic Production Process: Production
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Sustainability at Santen
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Digital Transformation (DX)
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Environment
Measures against Climate Change
Environmental Load Reduction
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Santen Initiatives
Santen Activities for Inclusive Society
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environmental Data 2022
Employment and Human Resources Data 2022
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2020
Information
2020 Information
RSS
Information
12.11.2020
Santen to Present Latest Data on MicroShunt at 14th EGS Congress
12.01.2020
Ciclosporin Topical Ophthalmic Emulsion, 0.1% in the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18, has been added to China's third batch of Overseas New Drugs Urgently Needed in Clinical Settings, compiled by the NMPA
10.26.2020
Santen Announces U.S. FDA Filling Acceptance of New Drug Application(NDA) for Cyclosporine Topical Ophthalmic Emulsion, 0.1% in the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18
10.02.2020
Santen China won the Best Ophthalmic Public Education Award at the 2020 Chinese Ophthalmologist Association (COA) Annual Conference
09.17.2020
Announcing Addition of Third Building to Shiga Product Supply Center's Site
09.17.2020
Integrated Report Santen Report 2020 has been published
09.14.2020
Santen, Verily Announce Joint Venture
08.06.2020
Corporate Social Responsibility (CSR) page on our website has been updated
06.23.2020
Santen's Proposed New Working Styles under the New Normal
06.17.2020
Announcement of New Long-Term Vision
05.19.2020
Santen's Measures to Combat Novel Coronavirus Infections (COVID-19) (No. 3)
04.01.2020
Santen Pharmaceutical measures to combat the disease caused by the novel coronavirus (COVID-19)
03.24.2020
Santen's Measures to Combat Novel Coronavirus Infections (COVID-19) (No. 2)
02.28.2020
Santen's Measures to Combat Novel Coronavirus Infections (COVID-19) (No. 1)
02.27.2020
Beware of Suspicious E-mails and Messages on Social Media Claiming to be from Santen Pharmaceutical Co., Ltd.
News Archive